 | • レポートコード：MRC2305B066 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、222ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に7,154.23百万ドルであった世界のオリゴヌクレオチド合成市場規模が、2022年には8,674.52百万ドルに達し、2027年までに年平均21.42％成長して22,932.88百万ドルになると予測しています。当調査資料では、オリゴヌクレオチド合成の世界市場について調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析（機器、試薬、合成オリゴ）、用途別分析（診断、研究、治療）、エンドユーザー別分析（学術研究機関、診断検査室、病院、製薬＆バイオテクノロジー企業）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目をまとめました。なお、当書に掲載されている企業情報には、Adtbio Agilent Technologies、Agilent Technologies, Inc.、Ajinomoto Bio-Pharma Services、Bio-synthesis Inc.、BioAutomation Corporation、Biogen Inc.、Danaher Corporation、Eurofins Genomics GmbH、Eurofins Genomics LLCなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のオリゴヌクレオチド合成市場規模：製品別 - 機器の市場規模 - 試薬の市場規模 - 合成オリゴの市場規模 ・世界のオリゴヌクレオチド合成市場規模：用途別 - 診断における市場規模 - 研究における市場規模 - 治療における市場規模 ・世界のオリゴヌクレオチド合成市場規模：エンドユーザー別 - 学術研究機関における市場規模 - 診断検査室における市場規模 - 病院における市場規模 - 製薬＆バイオテクノロジー企業における市場規模 ・世界のオリゴヌクレオチド合成市場規模：地域別 - 南北アメリカのオリゴヌクレオチド合成市場規模 アメリカのオリゴヌクレオチド合成市場規模 カナダのオリゴヌクレオチド合成市場規模 ブラジルのオリゴヌクレオチド合成市場規模 ... - アジア太平洋のオリゴヌクレオチド合成市場規模 日本のオリゴヌクレオチド合成市場規模 中国のオリゴヌクレオチド合成市場規模 インドのオリゴヌクレオチド合成市場規模 韓国のオリゴヌクレオチド合成市場規模 台湾のオリゴヌクレオチド合成市場規模 ... - ヨーロッパ/中東/アフリカのオリゴヌクレオチド合成市場規模 イギリスのオリゴヌクレオチド合成市場規模 ドイツのオリゴヌクレオチド合成市場規模 フランスのオリゴヌクレオチド合成市場規模 ロシアのオリゴヌクレオチド合成市場規模 ... - その他地域のオリゴヌクレオチド合成市場規模 ・競争状況 ・企業情報 |
The Global Oligonucleotide Synthesis Market size was estimated at USD 7,154.23 million in 2021 and expected to reach USD 8,674.52 million in 2022, and is projected to grow at a CAGR 21.42% to reach USD 22,932.88 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Oligonucleotide Synthesis to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Equipment, Reagents, and Synthesized Oligos. The Synthesized Oligos is further studied across Synthesized Oligos Market, By Product and Synthesized Oligos Market, By Type. The Synthesized Oligos Market, By Product is further studied across Intermediate-scale Synthesized Oligos, Large-scale Synthesized Oligos, Linkers & Adaptors, Oligonucleotide-based Drugs, Primers, and Probes. The Synthesized Oligos Market, By Type is further studied across Custom Oligos and Predesigned Oligos.
Based on Application, the market was studied across Diagnostic Applications, Research Applications, and Therapeutic Applications. The Research Applications is further studied across Gene Synthesis, Pcr, Qpcr, and Sequencing. The Therapeutic Applications is further studied across Cpg Oligonucleotide-based Therapies, Dna & Antisense Oligonucleotide-based Therapies, and Rnai Oligonucleotide-based Therapies.
Based on End User, the market was studied across Academic Research Institutes, Diagnostic Laboratories, Hospitals, and Pharmaceutical & Biotechnology Companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Oligonucleotide Synthesis market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Oligonucleotide Synthesis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Oligonucleotide Synthesis Market, including Adtbio Agilent Technologies, Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Bio-synthesis Inc., BioAutomation Corporation, Biogen Inc., Danaher Corporation, Eurofins Genomics GmbH, Eurofins Genomics LLC, Eurogentec S.A., Eurogentec SA, GE Healthcare Inc., Genscript Corporation, GenScript, Inc., Integrated DNA Technologies Inc., Merck KGaA, Nitto Denko Avecia Inc, Sarepta Therapeutics Inc, Thermo Fisher Scientific Inc., and TriLink BioTechnologies, Incorporated.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Oligonucleotide Synthesis Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Oligonucleotide Synthesis Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oligonucleotide Synthesis Market?
4. What is the competitive strategic window for opportunities in the Global Oligonucleotide Synthesis Market?
5. What are the technology trends and regulatory frameworks in the Global Oligonucleotide Synthesis Market?
6. What is the market share of the leading vendors in the Global Oligonucleotide Synthesis Market?
7. What modes and strategic moves are considered suitable for entering the Global Oligonucleotide Synthesis Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Usage of synthesized oligonucleotides in molecular diagnostics and clinical applications
5.1.1.2. Advancements in oligonucleotide synthesis
5.1.2. Restraints
5.1.2.1. High treatment cost of oligonucleotides
5.1.3. Opportunities
5.1.3.1. Rising R&D expenditure and government investment in pharmaceutical and biotechnology research
5.1.4. Challenges
5.1.4.1. Lack of skilled professionals and research support in underdeveloped countries
5.2. Cumulative Impact of COVID-19
6. Oligonucleotide Synthesis Market, by Product
6.1. Introduction
6.2. Equipment
6.3. Reagents
6.4. Synthesized Oligos
6.5.1. Synthesized Oligos Market, By Product
6.5.2.1. Intermediate-scale Synthesized Oligos
6.5.2.2. Large-scale Synthesized Oligos
6.5.2.3. Linkers & Adaptors
6.5.2.4. Oligonucleotide-based Drugs
6.5.2.5. Primers
6.5.2.6. Probes
6.5.2. Synthesized Oligos Market, By Type
6.5.3.1. Custom Oligos
6.5.3.2. Predesigned Oligos
7. Oligonucleotide Synthesis Market, by Application
7.1. Introduction
7.2. Diagnostic Applications
7.3. Research Applications
7.4.1. Gene Synthesis
7.4.2. Pcr
7.4.3. Qpcr
7.4.4. Sequencing
7.4. Therapeutic Applications
7.5.1. Cpg Oligonucleotide-based Therapies
7.5.2. Dna & Antisense Oligonucleotide-based Therapies
7.5.3. Rnai Oligonucleotide-based Therapies
8. Oligonucleotide Synthesis Market, by End User
8.1. Introduction
8.2. Academic Research Institutes
8.3. Diagnostic Laboratories
8.4. Hospitals
8.5. Pharmaceutical & Biotechnology Companies
9. Americas Oligonucleotide Synthesis Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Oligonucleotide Synthesis Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Oligonucleotide Synthesis Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Adtbio Agilent Technologies
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Agilent Technologies, Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Ajinomoto Bio-Pharma Services
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bio-synthesis Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. BioAutomation Corporation
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Biogen Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Danaher Corporation
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Eurofins Genomics GmbH
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Eurofins Genomics LLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Eurogentec S.A.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Eurogentec SA
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. GE Healthcare Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Genscript Corporation
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. GenScript, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Integrated DNA Technologies Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Merck KGaA
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Nitto Denko Avecia Inc
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sarepta Therapeutics Inc
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Thermo Fisher Scientific Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. TriLink BioTechnologies, Incorporated
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing